What type of study is this?

This is a Animal Study study (also classified as: In Vitro Study).

September 5, 2025

Data from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

View Full Paper

Ask AI

Bookmark

Authors

This study demonstrates CAR T cell therapy's effectiveness against multiple myeloma, suggesting CD229 as a new target when BCMA is reduced.

The bicistronic CAR T cell shows efficacy in models with limited BCMA expression.
In models with reduced BCMA, the CAR T cell targeting CD229 effectively controlled myeloma.
Monospecific CAR targeting CD229 validated its effectiveness in both in vitro and in vivo settings.
No fratricide was observed in CAR T cells, indicating a favorable safety profile.

Rodríguez‐Lobato et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 5, 2025

View Full Paper

Ask AI

Bookmark

Authors

This study demonstrates CAR T cell therapy's effectiveness against multiple myeloma, suggesting CD229 as a new target when BCMA is reduced.

The bicistronic CAR T cell shows efficacy in models with limited BCMA expression.
In models with reduced BCMA, the CAR T cell targeting CD229 effectively controlled myeloma.
Monospecific CAR targeting CD229 validated its effectiveness in both in vitro and in vivo settings.
No fratricide was observed in CAR T cells, indicating a favorable safety profile.

Rodríguez‐Lobato et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark